Get started
Inogen, IncInogen, IncInogen, Inc

Inogen, Inc

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

INGN trade ideas

INGN - Good ER - Insider buysInogen Inc is a medical technology company that develops and manufactures portable oxygen concentrators used to deliver oxygen therapy to patients with chronic respiratory conditions. Its key product, the Inogen One system, is a lightweight alternative to traditional, stationary oxygen concentrator systems and oxygen tanks. The firm sells its products to home medical equipment providers and also rents products directly to patients. Internationally, It sells its products through distributors large gas companies, and home oxygen providers. It generates the majority of its revenue in the United States. Disclaimer: The information provided here is for informational purposes only and is not intended as financial advice. Investment Overview (As of May 7, 2024): Shares in Float: 23.479 million Short Float: 7.75%, indicating a moderate interest from short sellers. Recent Activities: Positive earnings report on May 7, 2024, along with recent insider purchases, suggest growing confidence among company insiders about the firm's future prospects. Technical Analysis: Critical Resistance Levels: Key resistance levels are at $8.0, $9.0, $9.70, and $10.50. Breaking above these levels could indicate potential for further gains. Trading Strategy: Take Profit (TP): Consider setting profit targets around $13.70 to capitalize on potential upward moves. Stop Loss (SL): A stop loss around just below $6.0 can help manage risk and protect against larger losses. Chart Analysis: For detailed insights, it’s recommended to review specific chart analyses that include price movements, trend lines, and volume indicators. Such visual aids can provide a clearer understanding of potential price trajectories. Trading Caution: Engage in trading with strategies that match your market understanding and risk tolerance level. It's crucial to stay informed through continuous research or by consulting with financial advisors to align your trading decisions with your financial goals. Recommendation: Always consider enhancing your market analysis with comprehensive tools and resources, ensuring a well-rounded approach to trading.
NASDAQ:INGNLong
by meitshels_smell_trades
Go up!-Severely penalized, INGN reached the low point ultimately traced. -A large part of your penalty was due to numerous deficit balance sheets and, mainly, due to the increase in the American interest rate. We know that companies that depend on third-party capital to finance themselves are the ones that suffer the most. -In the monthly chart, oddly enough, the “SETUP used” is pointing to the possibility of an upward pivot. This is really amazing to me! We even have a fund formed. Even more incredible. -The weekly chart has already pointed and confirmed a bullish pivot, and we have prices always hovering above the head region of the bullish pivot at 11.35. -On the daily chart we have the bulls very shy, therefore, I don't rule out that prices may, before rising stronger, come to test the 10.79 region again as a strong point for a bottom. If prices do not lose the region of 10.79, an excellent buying window opens. We have just above the mega downtrend line and, if it is broken, the asset will be free to go up. -Worth a read! -Do your analysis and good business. -Be Conscious, If You Buy, Use Top! -See below for other graphic reviews!
NASDAQ:INGN
by MacD_Bollinger
My Favorite Stock for today May 8 2019So today i have found NASDAQ:INGN for a fade (short) trade, if you look at the 5 min chart you will see that we are under the VWAP, and the MA's with a big window to fade, i will trade it as soon as it breaks the USD64.00 level, with a window all the way to USD60.00, my stop will be 10 cents above the VWAP, remember that i only trade short bias and i am looking to locate Home Run trades, other wise i will not trade. This is for educational purposes.
NASDAQ:INGNShort
by leoamartinez
EXPOSED by Citron.1.) Average age of consumers are 75+, only 10% of its sales come from medicare. <---- UNACCEPTABLE 2.) WRONG INFO GIVEN BY RESELLERS TO CUSTOMERS. Per Citron: Citron estimates that Inogen sells about 90% of its POC units vs. only renting about 10% through Medicare. Assuming 40% of POC units were rented through Medicare, Inogen’s revenue would decline by about 20% while EPS would decline by about 80% due to the negative mix shift to Medicare’s much lower margins. Evidently, the multiple would see meaningful contraction as well. Citron jumps into muddy waters and assigns a conservative $46 target on Inogen. “On July 11, 2018, CMS released a new proposal to change the payment rules for Durable Medical Equipment Prosthetics, Orthotics, and Supplies (DMEPOS), including our portable oxygen concentrators. This includes a proposal that when the current competitive bidding contracts expire December 31, 2018, beneficiaries can obtain DMEPOS items from any enrolled Medicare supplier. ” Now that any DME can offer you a portable oxygen concentrator, Inogen will get much fewer Medicare leads that can be turned into cash sales. PLEASE READ Citron's report: citronresearch.com Per Muddy Water: "We believe management has created egregiously false narrative re TAM & growth. Real TAM is ~1. 3M users, not 3M as claimed. TAM is shrinking, NOT growing at 7%-10%."
NASDAQ:INGNShort
by UnknownUnicorn2993086
The hottest H.Care equipment stock right nowAt this point, I feel sorry for whoever's shorting this. Recorded $97 million on revenues this past Q2; +68% 200SMA, +24% 50SMA, +12% 20SMA, and backed by Medicare. Having worked in a hospital for so long and witnessed so many patients who will probably be in O2 the rest of their life, I can't believe that I ignored this company a few months ago. Who wants to carry an O2 tank forever? They are heavy and risky. I am just looking for a good entry point then I am in for the long haul. PT $350. If $ABMD is up there for cardiac then so should be $INGN for respiratory.
NASDAQ:INGNLong
by UnknownUnicorn2993086
1
O2 Saturation low. Oxygen needed ASAP!!!!!Inogen is increasing its full year 2018 total revenue guidance range to $345 to $355 million, up from $340 to $350 million, representing growth of 38.3% to 42.3% versus 2017 full year results. The Company still expects direct-to-consumer sales to be its fastest growing channel, domestic business-to-business sales to have a significant growth rate, and international business-to-business sales to have a solid growth rate. Why the Pullback? Operating expense included research and development expense of $2.1 million in the third quarter of 2018, which was up from $1.4 million in the comparative period in 2017, primarily due to increased personnel-related expenses. Sales and marketing expense increased to $26.3 million in the third quarter of 2018 versus $13.1 million in the comparative period in 2017, primarily due increased personnel-related expenses as the Company continued to hire inside sales representatives at its Cleveland facility and increased advertising expenditures. Inogen is reducing its guidance range for full year 2018 Adjusted EBITDA to $60 to $62 million, down from $65 to $69 million, representing growth of 18.0% to 22.0% versus 2017 full year results due to continued sales and marketing investments expected in the fourth quarter of 2018. via investor.inogen.com the market sucks
NASDAQ:INGN
by UnknownUnicorn2993086